L’Oréal has launched Melasyl, a molecule designed to prevent the development of skin pigmentation marks that can lead to age spots and post-acne marks.
The French beauty giant has introduced the molecule in La Roche Posay’s Mela B3 franchise, including MelaB3 serum and MelaB3 SPF30.
Melasyl was first presented at the World Congress of Dermatology 2023 in Singapore, alongside the first worldwide epidemiological study on pigmentary disorders.
Melasyl also featured at the American Academy of Dermatology’s annual meeting in San Diego this month.
Melanin enables the vast spectrum of human skin tones in all their diversity, with melanin production increasing following sun exposure to protect skin cells.
Many factors can upset normal melanin production, which can lead to localized pigmentation issues such as age spots and post-inflammatory marks.
L’Oréal said its formulations containing Melasyl improve the appearance of existing dark spots, including persistent ones, with clinically demonstrated efficacy and safety across all skin tones.
Melasyl is the result of rigorous tests involving 121 scientific studies.
“With half of all people reporting skin pigmentation issues and a third of these experiencing lower quality of life as a result, the impact of visible spots or post-acne marks is clearly more than skin-deep,” said Anne Colonna, Global Head of Advanced Research at L’Oréal Groupe.
“Melasyl is a first-of-its kind ingredient that helps to address localized skin pigmentation issues, with proven efficacy and wide accessibility that will enable more people to regain their self-confidence,” she added.
L’Oréal Paris and Vichy will follow with future product launches, expanding consumer access to expert formulations containing the new ingredient.
